![](https://bellpotter.com.au/wp-content/uploads/2024/07/AdobeStock_465265959-600x345.png)
![](https://bellpotter.com.au/wp-content/uploads/2024/07/AdobeStock_746017869-600x345.png)
3 July 2024
HUB24 Ltd (HUB): The platform of the future
We've initiated coverage on HUB24 (HUB), a specialist investment platform provider.
![](https://bellpotter.com.au/wp-content/uploads/2024/06/AdobeStock_711513259-600x345.png)
27 June 2024
Analyst Outlook June 2024
Our analysts provide their sector outlook and top stock picks for June 2024.
![](https://bellpotter.com.au/wp-content/uploads/2024/06/AdobeStock_609448926-600x345.png)
18 June 2024
Clinuvel Pharmaceuticals (CUV): Looking to Vitiligo
CUV are conducting two Phase 3 trials to expand the label of Scenesse to include patients with vitiligo.
![](https://bellpotter.com.au/wp-content/uploads/2024/06/AdobeStock_724877369-600x403.jpeg)
5 June 2024
The cycle appears to be turning
As we move closer to the halfway mark for CY24, the U.S. economy has displayed remarkable resilience, with stocks at near all-time highs and the S&P 500 defying forecasts for a slowdown.